ArticleVirchows Archiv : an international journal of pathology2009
Comparison of cyclooxygenase-2 and CD44 mRNA expression in colorectal cancer and its relevance for prognosis.
Article in Virchows Archiv : an international journal of pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 14 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated CD44 and COX-2 expression in colorectal cancer (CRC) and analyzed its relationship with the clinicopathological characteristics. The prognostic impact on patient survival was compared between the two proteins. CD44 and COX-2 mRNA levels in 42 primary CRCs were analyzed using quantitative real-time PCR, with normalization relative to GAPDH. The cycle threshold (Ct) values were measured, and results are expressed as the Ct ratios of CD44 or COX-2 to GAPDH. The COX-2 Ct ratio was much lower in cases of lymphovascular invasion by the tumor than for no invasion (P = 0.004). During follow-up for a median of 40 months, there was no significant difference in the median CD44 Ct ratio between survivors and non-survivors (P = 0.362), whereas the COX-2 Ct ratio was significantly associated with survival at the time of data analysis (P = 0.042). The survival of colorectal cancer patients with a high COX-2 Ct ratio was significantly longer than that of patients with a low COX-2 Ct ratio (P = 0.048). This study suggests that COX-2 expression has a more significant impact than CD44 expression on the survival of CRC patients. Further studies are needed to resolve these issues with a large sample size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.